[go: up one dir, main page]

BRPI0913726A2 - rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos - Google Patents

rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos

Info

Publication number
BRPI0913726A2
BRPI0913726A2 BRPI0913726A BRPI0913726A BRPI0913726A2 BR PI0913726 A2 BRPI0913726 A2 BR PI0913726A2 BR PI0913726 A BRPI0913726 A BR PI0913726A BR PI0913726 A BRPI0913726 A BR PI0913726A BR PI0913726 A2 BRPI0913726 A2 BR PI0913726A2
Authority
BR
Brazil
Prior art keywords
rapalogs
preparation
methods
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
BRPI0913726A
Other languages
English (en)
Inventor
Fajun Nan
Jian Ding
Jianping Zuo
Linghua Meng
Linqian Yu
Min Gu
Na Yang
Yangming Zhang
Original Assignee
Shanghai Inst Materia Medica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Inst Materia Medica filed Critical Shanghai Inst Materia Medica
Publication of BRPI0913726A2 publication Critical patent/BRPI0913726A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0913726A 2008-09-18 2009-09-17 rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos BRPI0913726A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200810200073XA CN101676291B (zh) 2008-09-18 2008-09-18 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
PCT/CN2009/001042 WO2010031251A1 (zh) 2008-09-18 2009-09-17 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
BRPI0913726A2 true BRPI0913726A2 (pt) 2015-10-13

Family

ID=42029020

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913726A BRPI0913726A2 (pt) 2008-09-18 2009-09-17 rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos

Country Status (8)

Country Link
US (1) US8455510B2 (pt)
EP (1) EP2351757A4 (pt)
JP (1) JP5394493B2 (pt)
CN (1) CN101676291B (pt)
BR (1) BRPI0913726A2 (pt)
CA (1) CA2737355C (pt)
MX (1) MX2011002783A (pt)
WO (1) WO2010031251A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5998198B2 (ja) * 2011-04-01 2016-09-28 サンド・アクチエンゲゼルシヤフト ラパマイシンのｃ−４２位の位置選択的アシル化
MX2013012596A (es) 2011-04-29 2014-08-21 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para generar linfocitos t reguladores cd8+.
AU2012275953B2 (en) * 2011-06-06 2015-01-22 Arbor Therapeutics, LLC Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents
BR112015027279A8 (pt) * 2013-05-03 2018-01-30 Selecta Biosciences Inc métodos e composições para acentuar células t reguladoras cd4+
WO2016023082A1 (en) 2014-08-12 2016-02-18 Monash University Lymph directing prodrugs
US20160074532A1 (en) 2014-09-07 2016-03-17 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
CN107072964A (zh) 2014-11-05 2017-08-18 西莱克塔生物科技公司 与低hlb表面活性剂在生产包含rapalog的合成纳米颗粒中之用途相关的方法和组合物
JP7118888B2 (ja) 2015-09-08 2022-08-16 モナッシュ ユニバーシティ リンパ指向性プロドラッグ
DK3426285T3 (da) 2016-03-11 2024-08-26 Cartesian Therapeutics Inc Formuleringer og doser af pegyleret uricase
WO2018064215A1 (en) 2016-09-27 2018-04-05 Selecta Biosciences, Inc. Recombinant immunotoxins for use in the treatment of cancer
JP2020506890A (ja) 2017-01-07 2020-03-05 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 合成ナノキャリアにカップリングした免疫抑制剤のパターン化された投与
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP4306524A3 (en) 2017-08-29 2024-09-11 PureTech LYT, Inc. Lymphatic system-directing lipid prodrugs
KR20200086670A (ko) 2017-10-13 2020-07-17 셀렉타 바이오사이언시즈, 인크. 항바이러스 전달 벡터 IgM 반응을 약화시키기 위한 방법 및 조성물
WO2019126374A1 (en) * 2017-12-19 2019-06-27 Ariya Therapeutics, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
CN112771070A (zh) 2018-07-16 2021-05-07 西莱克塔生物科技公司 Otc构建体和载体的方法和组合物
MX2021000638A (es) 2018-07-16 2021-06-23 Selecta Biosciences Inc Métodos y composiciones de construcciones y vectores de acidemia metilmalónica.
JP2022531201A (ja) 2019-04-28 2022-07-06 セレクタ バイオサイエンシーズ インコーポレーテッド ウイルス導入ベクターに対する既存の免疫を伴う対象の処置のための方法
CN114206396A (zh) 2019-05-28 2022-03-18 西莱克塔生物科技公司 用于减弱抗病毒转移载体免疫应答的方法和组合物
EP3980784A1 (en) 2019-06-04 2022-04-13 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
EP4048269A1 (en) 2019-10-21 2022-08-31 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
CN118384281A (zh) 2019-11-08 2024-07-26 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
WO2021159021A1 (en) 2020-02-05 2021-08-12 Puretech Lyt, Inc. Lipid prodrugs of neurosteroids
CA3173734A1 (en) 2020-02-26 2021-09-02 Selecta Biosciences, Inc. Methods and compositions using synthetic nanocarriers comprising immunosuppressant
EP4117631A1 (en) 2020-03-11 2023-01-18 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers
EP4135693A1 (en) 2020-04-14 2023-02-22 Selecta Biosciences, Inc. Methods and compositions for inducing autophagy
WO2022098901A1 (en) 2020-11-04 2022-05-12 Selecta Biosciences, Inc. Compositions for reducing immune responses against immunoglobulin proteases
CN114762696B (zh) * 2021-01-12 2024-01-30 上海科技大学 低氘水的用途及相关产品
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
CA3264659A1 (en) 2022-08-11 2024-02-15 Cartesian Therapeutics, Inc. COMPOSITIONS AND PROCESSES ASSOCIATED WITH IMMUNOGLOBULIN PROTEASES AND FUSION THEREOF
WO2024107889A1 (en) 2022-11-15 2024-05-23 Selecta Biosciences, Inc. Compositions and methods for treating primary biliary cholangitis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
WO1994025022A1 (en) * 1993-04-23 1994-11-10 Abbott Laboratories Rapamycin conjugates and antibodies
EP0729471A1 (en) * 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
DK1319008T3 (da) * 2000-09-19 2009-02-09 Wyeth Corp Vandoplöselige rapamycinestere
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
WO2005016252A2 (en) * 2003-07-11 2005-02-24 Ariad Gene Therapeutics, Inc. Phosphorus-containing macrocycles
AU2005238431A1 (en) * 2004-04-14 2005-11-10 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
US20090253733A1 (en) * 2008-04-02 2009-10-08 Biointeractions, Ltd. Rapamycin carbonate esters

Also Published As

Publication number Publication date
US8455510B2 (en) 2013-06-04
CN101676291A (zh) 2010-03-24
JP2012502930A (ja) 2012-02-02
CN101676291B (zh) 2012-05-09
JP5394493B2 (ja) 2014-01-22
WO2010031251A1 (zh) 2010-03-25
EP2351757A4 (en) 2012-05-02
EP2351757A1 (en) 2011-08-03
MX2011002783A (es) 2011-09-01
CA2737355C (en) 2015-01-13
CA2737355A1 (en) 2010-03-25
US20110166172A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
BRPI0913726A2 (pt) rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI0915680A2 (pt) miméticos de glicocorticoide, métodos de prepará-los, composições farmacêuticas, e usos dos mesmos
PT2963031T (pt) Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI1011876A2 (pt) "composição farmacêutica estável e métodos de uso da mesma"
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BRPI0918502A2 (pt) aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BR112013016772A2 (pt) composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
BRPI0822337A2 (pt) Folatos, composições e usos dos mesmos
BRPI0907628A2 (pt) Derivados bicíclicos de carboxamidas azabicíclicas, preparação dos mesmos e uso terapêutico dos mesmos
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]